265 related articles for article (PubMed ID: 9933662)
1. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
[TBL] [Abstract][Full Text] [Related]
2. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
Mortimer JE; Dehdashti F; Siegel BA; Trinkaus K; Katzenellenbogen JA; Welch MJ
J Clin Oncol; 2001 Jun; 19(11):2797-803. PubMed ID: 11387350
[TBL] [Abstract][Full Text] [Related]
3. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
5. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
6. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
Linden HM; Stekhova SA; Link JM; Gralow JR; Livingston RB; Ellis GK; Petra PH; Peterson LM; Schubert EK; Dunnwald LK; Krohn KA; Mankoff DA
J Clin Oncol; 2006 Jun; 24(18):2793-9. PubMed ID: 16682724
[TBL] [Abstract][Full Text] [Related]
7. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
[TBL] [Abstract][Full Text] [Related]
8. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study.
Inoue T; Kim EE; Wallace S; Yang DJ; Wong FC; Bassa P; Cherif A; Delpassand E; Buzdar A; Podoloff DA
Cancer Biother Radiopharm; 1996 Aug; 11(4):235-45. PubMed ID: 10851543
[TBL] [Abstract][Full Text] [Related]
10. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer.
Katzenellenbogen JA; Welch MJ; Dehdashti F
Anticancer Res; 1997; 17(3B):1573-6. PubMed ID: 9179196
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
12. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
13. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Linden HM; Kurland BF; Peterson LM; Schubert EK; Gralow JR; Specht JM; Ellis GK; Lawton TJ; Livingston RB; Petra PH; Link JM; Krohn KA; Mankoff DA
Clin Cancer Res; 2011 Jul; 17(14):4799-805. PubMed ID: 21750198
[TBL] [Abstract][Full Text] [Related]
14. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma.
McGuire AH; Dehdashti F; Siegel BA; Lyss AP; Brodack JW; Mathias CJ; Mintun MA; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1991 Aug; 32(8):1526-31. PubMed ID: 1869973
[TBL] [Abstract][Full Text] [Related]
15. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins.
Jonson SD; Welch MJ
Q J Nucl Med; 1998 Mar; 42(1):8-17. PubMed ID: 9646640
[TBL] [Abstract][Full Text] [Related]
18. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract][Full Text] [Related]
19. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
[TBL] [Abstract][Full Text] [Related]
20. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C
J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
